Valion Bio (VBIO) Net Equity Issued and Repurchased (2023 - 2025)
Valion Bio (VBIO) posted quarterly Net Equity Issued and Repurchased of $429000.0 for Q3 2025, up 113.2% year-over-year from $201223.3 in Q3 2024, and up 113.2% quarter-over-quarter from -$3.3 million in Q3 2024.
Valion Bio (VBIO) Net Equity Issued and Repurchased (2023 - 2025) Analysis & Trends
Valion Bio's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $429000.0 for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased rose 113.2% year-over-year to $429000.0; the TTM figure through Dec 2025 stood at -$2.8 million (down 364.98% YoY), while the FY2025 annual figure was $2.3 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at $429000.0, up from -$3.3 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $4.3 million in Q3 2023, with the low at -$3.3 million in Q3 2024.
- The 3-year median for Net Equity Issued and Repurchased is $2.3 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased tumbled 175.32% in 2024, then surged 113.2% in 2025.
- Valion Bio's Net Equity Issued and Repurchased stood at $4.3 million in 2023, then plunged by 175.32% to -$3.3 million in 2024, then surged by 113.2% to $429000.0 in 2025.
- Business Quant data shows VBIO's Net Equity Issued and Repurchased at $429000.0 in Q3 2025, -$3.3 million in Q3 2024, and $4.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Valion Bio | 405,599.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 429,000.00 |
| Sep 30, 2025 | 429,000.00 |
| Sep 30, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.25 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Mar 31, 2023 | 4.19 Mn |
| Mar 31, 2023 | 4.19 Mn |